Weight changes after hospitalization for worsening heart failure and subsequent re-hospitalization and mortality in the EVEREST trial

John E A Blair, Sadiya Khan, Marvin A. Konstam, Karl Swedberg, Faiez Zannad, John C Jr. Burnett, Liliana Grinfeld, Aldo P. Maggioni, James E. Udelson, Christopher A. Zimmer, John Ouyang, Chien Feng Chen, Mihai Gheorghiade

Research output: Contribution to journalArticle

60 Citations (Scopus)

Abstract

Aims increases in body weight (BW) are important determinants for hospitalization in ambulatory patients with heart failure (HF), but have not yet been explored in patients hospitalized for worsening HF. We explore the relationship between change in BW after hospitalization for worsening HF and risk for repeat hospitalization and mortality in the EVEREST trial.Methods and resultsThe EVEREST trial randomized 4133 patients hospitalized for worsening HF and low ejection fraction (≤40) to tolvaptan, a vasopressin antagonist, or placebo. Following discharge, BW was assessed at 1, 4, and 8 weeks, and every 8 weeks thereafter. A time-dependent Cox proportional Hazard model explored the relationship between change in BW at 60, 120, and 180 days from discharge and the risks of HF hospitalization, cardiovascular (CV) hospitalization, and all-cause mortality. For subjects re-hospitalized for heart failure at 60, 120, and 180 days after discharge, mean BW increase prior to the event was 1.96, 2.07, and 1.97 kg, respectively, compared with 0.74, 0.90, and 1.04 kg in patients without re-hospitalization (P < 0.001 all groups). A similar pattern was observed with CV hospitalization. However, increases in BW were not predictive of all-cause mortality.ConclusionIncreases in BW after hospitalization for worsening HF was predictive of repeat hospitalization events, but not mortality in the post-discharge period.

Original languageEnglish (US)
Pages (from-to)1666-1673
Number of pages8
JournalEuropean Heart Journal
Volume30
Issue number13
DOIs
StatePublished - Jul 2009

Fingerprint

Hospitalization
Heart Failure
Weights and Measures
Mortality
Body Weight
Body Weight Changes
Proportional Hazards Models
Placebos

Keywords

  • Body weight
  • Heart failure hospitalizations
  • Outcomes

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Weight changes after hospitalization for worsening heart failure and subsequent re-hospitalization and mortality in the EVEREST trial. / Blair, John E A; Khan, Sadiya; Konstam, Marvin A.; Swedberg, Karl; Zannad, Faiez; Burnett, John C Jr.; Grinfeld, Liliana; Maggioni, Aldo P.; Udelson, James E.; Zimmer, Christopher A.; Ouyang, John; Chen, Chien Feng; Gheorghiade, Mihai.

In: European Heart Journal, Vol. 30, No. 13, 07.2009, p. 1666-1673.

Research output: Contribution to journalArticle

Blair, JEA, Khan, S, Konstam, MA, Swedberg, K, Zannad, F, Burnett, JCJ, Grinfeld, L, Maggioni, AP, Udelson, JE, Zimmer, CA, Ouyang, J, Chen, CF & Gheorghiade, M 2009, 'Weight changes after hospitalization for worsening heart failure and subsequent re-hospitalization and mortality in the EVEREST trial', European Heart Journal, vol. 30, no. 13, pp. 1666-1673. https://doi.org/10.1093/eurheartj/ehp144
Blair, John E A ; Khan, Sadiya ; Konstam, Marvin A. ; Swedberg, Karl ; Zannad, Faiez ; Burnett, John C Jr. ; Grinfeld, Liliana ; Maggioni, Aldo P. ; Udelson, James E. ; Zimmer, Christopher A. ; Ouyang, John ; Chen, Chien Feng ; Gheorghiade, Mihai. / Weight changes after hospitalization for worsening heart failure and subsequent re-hospitalization and mortality in the EVEREST trial. In: European Heart Journal. 2009 ; Vol. 30, No. 13. pp. 1666-1673.
@article{dc3b44ebf22b49caad784359cafcb2b3,
title = "Weight changes after hospitalization for worsening heart failure and subsequent re-hospitalization and mortality in the EVEREST trial",
abstract = "Aims increases in body weight (BW) are important determinants for hospitalization in ambulatory patients with heart failure (HF), but have not yet been explored in patients hospitalized for worsening HF. We explore the relationship between change in BW after hospitalization for worsening HF and risk for repeat hospitalization and mortality in the EVEREST trial.Methods and resultsThe EVEREST trial randomized 4133 patients hospitalized for worsening HF and low ejection fraction (≤40) to tolvaptan, a vasopressin antagonist, or placebo. Following discharge, BW was assessed at 1, 4, and 8 weeks, and every 8 weeks thereafter. A time-dependent Cox proportional Hazard model explored the relationship between change in BW at 60, 120, and 180 days from discharge and the risks of HF hospitalization, cardiovascular (CV) hospitalization, and all-cause mortality. For subjects re-hospitalized for heart failure at 60, 120, and 180 days after discharge, mean BW increase prior to the event was 1.96, 2.07, and 1.97 kg, respectively, compared with 0.74, 0.90, and 1.04 kg in patients without re-hospitalization (P < 0.001 all groups). A similar pattern was observed with CV hospitalization. However, increases in BW were not predictive of all-cause mortality.ConclusionIncreases in BW after hospitalization for worsening HF was predictive of repeat hospitalization events, but not mortality in the post-discharge period.",
keywords = "Body weight, Heart failure hospitalizations, Outcomes",
author = "Blair, {John E A} and Sadiya Khan and Konstam, {Marvin A.} and Karl Swedberg and Faiez Zannad and Burnett, {John C Jr.} and Liliana Grinfeld and Maggioni, {Aldo P.} and Udelson, {James E.} and Zimmer, {Christopher A.} and John Ouyang and Chen, {Chien Feng} and Mihai Gheorghiade",
year = "2009",
month = "7",
doi = "10.1093/eurheartj/ehp144",
language = "English (US)",
volume = "30",
pages = "1666--1673",
journal = "European Heart Journal",
issn = "0195-668X",
publisher = "Oxford University Press",
number = "13",

}

TY - JOUR

T1 - Weight changes after hospitalization for worsening heart failure and subsequent re-hospitalization and mortality in the EVEREST trial

AU - Blair, John E A

AU - Khan, Sadiya

AU - Konstam, Marvin A.

AU - Swedberg, Karl

AU - Zannad, Faiez

AU - Burnett, John C Jr.

AU - Grinfeld, Liliana

AU - Maggioni, Aldo P.

AU - Udelson, James E.

AU - Zimmer, Christopher A.

AU - Ouyang, John

AU - Chen, Chien Feng

AU - Gheorghiade, Mihai

PY - 2009/7

Y1 - 2009/7

N2 - Aims increases in body weight (BW) are important determinants for hospitalization in ambulatory patients with heart failure (HF), but have not yet been explored in patients hospitalized for worsening HF. We explore the relationship between change in BW after hospitalization for worsening HF and risk for repeat hospitalization and mortality in the EVEREST trial.Methods and resultsThe EVEREST trial randomized 4133 patients hospitalized for worsening HF and low ejection fraction (≤40) to tolvaptan, a vasopressin antagonist, or placebo. Following discharge, BW was assessed at 1, 4, and 8 weeks, and every 8 weeks thereafter. A time-dependent Cox proportional Hazard model explored the relationship between change in BW at 60, 120, and 180 days from discharge and the risks of HF hospitalization, cardiovascular (CV) hospitalization, and all-cause mortality. For subjects re-hospitalized for heart failure at 60, 120, and 180 days after discharge, mean BW increase prior to the event was 1.96, 2.07, and 1.97 kg, respectively, compared with 0.74, 0.90, and 1.04 kg in patients without re-hospitalization (P < 0.001 all groups). A similar pattern was observed with CV hospitalization. However, increases in BW were not predictive of all-cause mortality.ConclusionIncreases in BW after hospitalization for worsening HF was predictive of repeat hospitalization events, but not mortality in the post-discharge period.

AB - Aims increases in body weight (BW) are important determinants for hospitalization in ambulatory patients with heart failure (HF), but have not yet been explored in patients hospitalized for worsening HF. We explore the relationship between change in BW after hospitalization for worsening HF and risk for repeat hospitalization and mortality in the EVEREST trial.Methods and resultsThe EVEREST trial randomized 4133 patients hospitalized for worsening HF and low ejection fraction (≤40) to tolvaptan, a vasopressin antagonist, or placebo. Following discharge, BW was assessed at 1, 4, and 8 weeks, and every 8 weeks thereafter. A time-dependent Cox proportional Hazard model explored the relationship between change in BW at 60, 120, and 180 days from discharge and the risks of HF hospitalization, cardiovascular (CV) hospitalization, and all-cause mortality. For subjects re-hospitalized for heart failure at 60, 120, and 180 days after discharge, mean BW increase prior to the event was 1.96, 2.07, and 1.97 kg, respectively, compared with 0.74, 0.90, and 1.04 kg in patients without re-hospitalization (P < 0.001 all groups). A similar pattern was observed with CV hospitalization. However, increases in BW were not predictive of all-cause mortality.ConclusionIncreases in BW after hospitalization for worsening HF was predictive of repeat hospitalization events, but not mortality in the post-discharge period.

KW - Body weight

KW - Heart failure hospitalizations

KW - Outcomes

UR - http://www.scopus.com/inward/record.url?scp=66949129107&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=66949129107&partnerID=8YFLogxK

U2 - 10.1093/eurheartj/ehp144

DO - 10.1093/eurheartj/ehp144

M3 - Article

C2 - 19411662

AN - SCOPUS:66949129107

VL - 30

SP - 1666

EP - 1673

JO - European Heart Journal

JF - European Heart Journal

SN - 0195-668X

IS - 13

ER -